Keywords
How to Cite
Abstract
Pemphigus foliaceus is an autoimmune bullous dermatosis caused by the action of antibodies against epidermal cells and is considered as the most frequent pemphigus complex disease that affects pets. It is characterized by the presence of intraepidermal pustules that may evolve into erosion, scaling, crusts, and alopecia, affecting the periocular area, nasal planum, ventral area, abdomen, and paw pads. The diagnosis is made by observing the animal’s history, anamnesis, clinical signs, and laboratory tests such as cytological examination and is confirmed by histopathology. The recommended treatment is systemic immunosuppressive therapy, such as prednisone or prednisolone. This study reports the treatment of a male German Spitz canine with oral oclacitinib who was diagnosed with pemphigus foliaceus that was unresponsive to oral corticosteroids. Oclacitinib was effective in treating pemphigus foliaceus and may be a new therapeutic option for this dermatopathy.
References
Abreu, C. R., Ondani, A. C., Parpinelli, A. C., Pereira, L. F., & Dias, F. G. G. (2014). Pênfigo foliáceo canino refratário ao tratamento com corticóide sistêmico: Relato de caso. Enciclopédia Biosfera, Centro Científico Conhecer, 10(18), 2280-2287.
Alves, H. M., Alves, L. M., Reis, M. F. S., & Romani, A. F. (2014). Pênfigo foliáceo canino: Relato de caso. Enciclopédia Biosfera, Centro Científico Conhecer, 10(19), 1438-1445.
Aymeric, E., & Bensignor, E. (2017). A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib. Veterinary Dermatology, 28(5), e123. http://doi.org/10.1111/vde.12458. PMid:28635010.
Barbosa, M. V. F. (2012). Patofisiologia do pênfigo foliáceo em cães: Revisão de literatura. Revista Científica Medicina Veterinária, 6(3), 26-31.
Carrasco, I., Martinez, M., & Albinyana, G. (2021). Beneficial effect of oclacitinib in a case of feline. Veterinary Dermatology, 32(3), 299-301. http://doi.org/10.1111/vde.12949. PMid:33720467.
Conceição, L. G. (2004). Biopsia e histopatologia da pele: um valioso recurso diagnostico na dermatologia: Revisão de literatura – parte 1. Clínica Veterinária, 51, 36-44.
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Martin, D. D., Walsh, K. F., Harfst, J. A., Follis, S. L., King, V. L., Boucher, J. F., & Stegemann, M. R. (2013a). Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatites. Veterinary Dermatology, 24(5), 479-487. http://doi.org/10.1111/ vde.12047. PMid:23829933.
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. F., Follis, S. I., King, V. I., Tena, J. K., & Stegemann, M. R. (2013b). A blinded, randomized, placebo-controlle trial of the efficacy and safety of the Janus kinase inibitor oclacitinib in cliente-owned dogs wiith atopic dermatites. Veterinary Dermatology, 24(142), 587-597. http://doi.org/10.1111/vde.12088. PMid:24581322.
Galati, L. H. H., Larsson Junior, C. E., Merlo, A., & Larsson, C. E. (2018). Avaliação dos efeitos do uso do oclacitinib sobre o score de prurido segundo escalas quantitativas linear e qualitativa de Yazbek-Larsson em cães com dermatite atópica no Serviço Dermatológico da FMVZ/USP. Revista Clínica Veterinária, 23(135), 60-72.
Gonzales, A. J., Bowman, J. W., Fici, G. J., Zhang, M., & Mann, D. W. (2014). Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics, 37, 317-324. http://doi.org/10.1111/jvp.12101. PMid:24495176.
Harvey, R. G., Olivrī, A., Lima, T., & Olivry, T. (2023). Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases. Veterinary Dermatology, 34(1), 53-58. http://doi.org/10.1111/vde.13128. PMid:36229964.
Hernandez-Bures, A., Bidot, W. A., Griffin, C. E., & Rosenkrantz, W. S. (2023). The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis. Veterinary Dermatology, 34(6), 554-566. http://doi.org/10.1111/vde.13203. PMid:37700599.
Howell, M. D., Kuo, F. I., & Smith, P. A. (2019). Targeting the janus kinase family in autoimmune skin diseases. Frontiers in Immunology, 10, 2342. http://doi.org/10.3389/fimmu.2019.02342. PMid:31649667.
Juczynska, K., Wozniacka, A., Waszczykowska, E., Danilewicz, M., Wągrowska-Danilewicz, M., & Zebrowska, A. (2020). Expression of JAK3, STAT2, STAT4, and STAT6 in pemphigus vulgaris. Immunologic Research, 20(2), 97. http://doi.org/10.1007/s12026-020-09122-y. PMid:32170648.
Levy, B. J., Linder, K. E., & Olivry, T. M. (2019). The role of oclacitinib in the menagement of ischaemic dermatopathy in four dogs. Veterinary Dermatology, 30(3), e63. http://doi.org/10.1111/vde.12743. PMid:31006925.
Lima, A. K., & Cunha, F. R. (2022). Uso do oclacitinib no tratamento de lúpus eritematoso cutâneo vesicular em cão da raça Border Collie: Relato de caso. Research, Society and Development, 11(15), e332111536033. http://doi.org/10.33448/rsd-v11i15.36033.
Medleau, L. M., & Hlinica, K. A. (2003). Dermatologia de pequenos animais: atlas colorido e guia terapêutico. São Paulo: Roca.
Mencalha, R. N. (2019). Atlas de dermatologia em cães e gatos - de A a Z (1. ed.). Curitiba. MedVep.
Miller, W. H., Griffin, C. E., & Campbell, K. L. (2013). Muller and Kirk’s small animal dermatology (7th ed., 948 p.). St Louis: Elsevier.
O’Shea, J. J., Kontzias, A., Yamaoka, K., Tanaka, Y., & Laurence, A. (2013). Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases, 72(2, Suppl 2), ii111-ii115. http://doi.org/10.1136/annrheumdis-2012-202576. PMid:23532440.
Pereira, B. J., Nunes, L. C., Martins Filho, S., & Costa, F. S. (2011). Avaliação dos efeitos da terapia com prednisona em cães utilizando análises ultrassonográfica, citopatológica e histopatológica. Revista Ceres, 58(5), 561-566. http://doi.org/10.1590/S0034-737X2011000500005.
Koch, S. N., Torres, S. M. F., & Plumb, D. C. (2012). Canine and feline dermatology drug handbook (1st ed.). Oxford: Wiley-Blackwell. http://doi.org/10.1002/9781118704745.
Raskin, E. R., & Meyer, D. J. (2012). Citologia: Clínica de cães e gatos (2. ed.). Rio de Janeiro. Elsevier.
Rhodes, K. H., & Werner, A. H. (2014). Dermatologia em pequenos animais (2. ed.). São Paulo: Roca.
Simpson, A. C., Schissler, J. R., Rosychuk, R. A. W., & Moore, A. R. (2017). The frequency of urinary tract and subclinical bacteriúria in dogs with allergic dermatites treated with oclacitinib: A prospective study. Veterinary Dermatology, 28(5), 485-491. http://doi.org/10.1111/vde.12450. PMid:28513001.
Tavakolpour, S. (2018). Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. Dermatologic Therapy, 31(5), e1296. http://doi.org/10.1111/dth.12696. PMid:30207045.
Zhou, Z., Corner, S., Petersen, A., Rosser, E., & Noland, E. L. (2021). Clinical presentation, treatment and outcome in dogs with pemphigus foliaceus with and without vasculopathic lesions: An evaluation of 41 cases. Veterinary Dermatology, 32(5), 503-e139. http://doi.org/10.1111/vde.12996. PMid:34189786.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Millene Macieira Carneiro da Silva, Márcia Bernardini, Natália Lôres Lopes